Study identifies target for disease hyper progression after immunotherapy in kidney cancer
Researchers find that cancer cells mimic myeloid cells to hide from the immune system and promote disease hyper progression after immunotherapy
Inhibiting the myeloid mimicry pathway along with immunotherapy improves antitumor outcomes in preclinical models
Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called “myeloid mimicry” to hide...
HER2-targeted therapy shows promising results in rare bile duct cancers
HER2-positive metastatic biliary tract cancer (BTC) is a rare and aggressive cancer with limited treatment options
Final results from the...
Researchers identify rare mutation that predicts strong immunotherapy response in colorectal cancer
A specific subset of POLE gene mutation, called loss-of-proofreading (LOP) mutations, makes colorectal tumors highly responsive to immunotherapy...
MD Anderson experts spotlight key immunotherapy advances at 2025 SITC Annual Meeting
Major themes include strategies to reprogram the tumor microenvironment and prevent cancer before it starts
New insights from AI-based imaging, B-cell biology and mRNA vaccine technology point to more personalized and long-lasting cancer immunotherapies
Research reveals that genetic mutations, neural signaling and microbiome composition play critical roles in modulating resistance to immunotherapy
NATIONAL HARBOR, MD, NOVEMBER 7,...
